Thomas Hennebry, MD
Interventional Cardiology · Oklahoma City, OKNPI 1881662070
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,463 of the $15,378 with a category attached, or 87.5%. Abbott accounts for 89.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $5,750 and has fallen 91.2% since, to $508 in 2025.
Across 75 payments — averaging $205.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$14K
- Abiomed$325
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
- Medtronic$199
- Amgen$149
- Terumo Medical Corporation$124
- plus $453 from 11 others
Across 39 payments — averaging $1049.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Surmodics, Inc.$23K
- Abbott$16K
- Roche Diagnostics Operations, Inc.$2K
What the payments were for
- Consulting fees$13,46388%
- Travel & lodging$220%
- Food & beverage$1,89412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $13,833 |
| Abiomed | 4 | $325 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $297 |
| Medtronic | 2 | $199 |
| Amgen | 2 | $149 |
| Terumo Medical Corporation | 1 | $124 |
| Heartflow, Inc. | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Boston Scientific | 3 | $52 |
| Novo Nordisk | 3 | $46 |
| Philips North America LLC | 1 | $44 |
| Chiesi USA, Inc. | 2 | $36 |
| Pfizer | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
| Surmodics, Inc. | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$13,400
- Impella$256
- TR Band$124
- Repatha$117
- CARDIOMEMS$114
- HawkOne$112
- HeartMate 3 Left Ventricular Assist Device$108
- FFRct$100
How this compares
$15,378 in reported general payments places this provider in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 675 | $720,141 |
| XareltoRivaroxaban | 97 | $109,870 |
| EntrestoSacubitril/Valsartan | 20 | $33,420 |
| JardianceEmpagliflozin | 14 | $29,046 |
| Repatha SureclickEvolocumab | 28 | $18,952 |
| BrilintaTicagrelor | 23 | $11,493 |
| Eplerenone | 123 | $11,283 |
| Metoprolol Succinate | 648 | $10,908 |
| ClopidogrelClopidogrel Bisulfate | 587 | $10,634 |
| Ranolazine ErRanolazine | 109 | $9,873 |
| Atorvastatin Calcium | 609 | $9,546 |
| LivaloPitavastatin Calcium | 17 | $8,367 |
| Repatha SyringeEvolocumab | 16 | $7,507 |
| Nebivolol Hcl | 131 | $7,100 |
| Prasugrel Hcl | 105 | $5,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $720,141675 claims |
| AstraZenecaBrilinta | $15 | $11,49323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.